about
sameAs
Role of a conserved active site cation-pi interaction in Escherichia coli serine hydroxymethyltransferaseMoonlighting by Different Stressors: Crystal Structure of the Chaperone Species of a 2-Cys PeroxiredoxinThe crystal structure of archaeal serine hydroxymethyltransferase reveals idiosyncratic features likely required to withstand high temperaturesAminoacylation and conformational properties of yeast mitochondrial tRNA mutants with respiratory deficiency.Yeast as a model of human mitochondrial tRNA base substitutions: investigation of the molecular basis of respiratory defectsAssessment of homology-based predictions in CASP5.Antibody modeling: implications for engineering and design.Structural and functional role of bases 32 and 33 in the anticodon loop of yeast mitochondrial tRNAIleSelective targeting of melanoma by PEG-masked protein-based multifunctional nanoparticles.Insights into the catalytic mechanism of glutathione S-transferase: the lesson from Schistosoma haematobium.One ring (or two) to hold them all – on the structure and function of protein nanotubes.In Vivo Targeting of Cutaneous Melanoma Using an Melanoma Stimulating Hormone-Engineered Human Protein Cage with Fluorophore and Magnetic Resonance Imaging Tracers.Antibody-drug conjugates: targeting melanoma with cisplatin encapsulated in protein-cage nanoparticles based on human ferritin.The phenotypic expression of mitochondrial tRNA-mutations can be modulated by either mitochondrial leucyl-tRNA synthetase or the C-terminal domain thereof.The isolated carboxy-terminal domain of human mitochondrial leucyl-tRNA synthetase rescues the pathological phenotype of mitochondrial tRNA mutations in human cellsExploring the cytochrome c folding mechanism: cytochrome c552 from thermus thermophilus folds through an on-pathway intermediate.Isoleucyl-tRNA synthetase levels modulate the penetrance of a homoplasmic m.4277T>C mitochondrial tRNA(Ile) mutation causing hypertrophic cardiomyopathy.Site-specific proteolytic degradation of IgG monoclonal antibodies expressed in tobacco plants.Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the alpha 5 beta 1 integrin.Can yeast be used to study mitochondrial diseases? Biolistic tRNA mutants for the analysis of mechanisms and suppressors.A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through alpha5beta1 integrin.Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide.Analysis and assessment of comparative modeling predictions in CASP4.Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.The folding pathway of an engineered circularly permuted PDZ domain.The yeast model suggests the use of short peptides derived from mt LeuRS for the therapy of diseases due to mutations in several mt tRNAs.Sequence conservation in families whose members have little or no sequence similarity: the four-helical cytokines and cytochromes.Protein Structure PredictionHb(αα,ββ): A novel fusion construct for a dimeric, four-domain hemoglobinA single-chain antibody fragment is functionally expressed in the cytoplasm of both Escherichia coli and transgenic plantsA novel chimera: the "truncated hemoglobin-antibiotic monooxygenase" from Streptomyces avermitilis
P50
Q27658040-E5B45761-9533-46F8-9FFB-C324431A7762Q27677957-DC20C810-92D1-4D50-BB73-F17DC0FFCDD6Q27695650-A1B8254E-6626-4FD8-AA6E-81448357482BQ29048143-5EB301B1-E2A0-47EF-9EF3-4F40E84082B5Q29048147-17296768-0A6B-4D05-8159-240BE4C373B0Q30336223-7B05DA54-2178-4EC3-9D0B-68D24A2A66CCQ33849928-534F8FE5-A36C-4B17-B593-C75FC4887D71Q35411940-8F85FA59-D8CC-402D-ADBD-5C9883E72EBFQ35972603-4AA43081-8FCE-4352-824A-5F384E6A9748Q36254174-873789DD-90C4-4A8A-81E5-54128D2BFE46Q38522745-A48A5FE3-5986-446F-94E0-FAA3D5AC463AQ38841399-CD652974-B6CD-4B3B-A3EF-39165D1CE0F3Q39073317-0B48646D-7EE4-4D92-BFCD-CC404E2076D7Q41807073-A32C01A7-C4E4-4DE2-8E1E-4405791B45DEQ41963195-A0EC9B63-17D0-4875-99C5-53EBB4A3B71DQ42169209-CA2D062F-4E63-4DCA-B2E4-AF3F83D00F1CQ44094488-0CE15A2D-961E-4B31-91C6-44B6436586F4Q44272919-41CC870F-534F-4F65-8560-E0380DB852F5Q44514708-E90D61CA-31B1-48CA-AF88-7444CE2CAAC3Q44777467-E0808529-EF11-46F0-AA0E-9A29677A26E5Q46815664-7CE29F34-540A-4E0A-95E8-A290DB608C5AQ47593215-5A020C27-A093-4F0D-9A58-391D0E37908CQ47616798-AC070446-E547-4BA6-BD2A-DE217F6F3AEFQ47875254-770D3C32-58D0-4041-BF1A-5271BD821EBDQ47991365-82ECAAD1-4649-4197-AE28-AA0BFD6FB8C8Q51694923-B7F2BBE8-0395-485B-A0E1-303AD91353BEQ54538729-B06DA6D5-89F2-4D8C-AE5E-7894B364ECB8Q57001166-ED40A931-B95C-407C-97A0-187F28D270D6Q59279550-B0C6EE70-4BB9-4D08-A434-4A969D2B801AQ63185825-62600D49-7F65-47A1-A412-C824ADFA38D2Q80490830-E96F396E-1683-4C13-A1F1-C2E88F559D46
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Veronica Morea
@ast
Veronica Morea
@en
Veronica Morea
@es
Veronica Morea
@nl
Veronica Morea
@sl
type
label
Veronica Morea
@ast
Veronica Morea
@en
Veronica Morea
@es
Veronica Morea
@nl
Veronica Morea
@sl
prefLabel
Veronica Morea
@ast
Veronica Morea
@en
Veronica Morea
@es
Veronica Morea
@nl
Veronica Morea
@sl
P106
P1153
6602100079
P21
P31
P496
0000-0003-2566-3049